Search

Your search keyword '"Venditti FJ"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Venditti FJ" Remove constraint Author: "Venditti FJ"
84 results on '"Venditti FJ"'

Search Results

1. Length of stay and 30 day mortality in patients suffering an uncomplicated ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in New York State

4. A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease.

5. New York Risk Model and Simplified Risk Score for In-Hospital/30-Day Mortality for Percutaneous Coronary Intervention.

6. Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main Disease.

7. Impact of COVID-19 on percutaneous coronary intervention utilization and mortality in New York.

9. Short-term Deaths After Percutaneous Coronary Intervention Discharge: Prevalence, Risk Factors, and Hospital Risk-Adjusted Mortality.

10. Relation of Operator Volume and Access Site to Short-Term Mortality in Radial Versus Femoral Access for Primary Percutaneous Coronary Intervention.

11. Percutaneous Coronary Intervention With and Without Intravascular Ultrasound for Patients With Complex Lesions: Utilization, Mortality, and Target Vessel Revascularization.

12. The Association of Socioeconomic Factors With Percutaneous Coronary Intervention Outcomes.

13. Hybrid coronary revascularization vs . percutaneous coronary interventions for multivessel coronary artery disease.

14. Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before and During COVID in New York.

15. Assessment of repeat target lesion percutaneous coronary intervention as a quality measure for public reporting and general quality assessment for PCIs.

16. Sex differences in the treatment and outcomes of patients hospitalized with ST-elevation myocardial infarction.

17. Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019.

18. Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery.

19. 2017 Versus 2012 Appropriate Use Criteria for Percutaneous Coronary Interventions: Impact on Appropriateness Ratings.

20. Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization.

21. Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.

22. Changes in Percutaneous Coronary Interventions Deemed "Inappropriate" by Appropriate Use Criteria.

23. The Impact of Excluding Shock Patients on Hospital and Physician Risk-Adjusted Mortality Rates for Percutaneous Coronary Interventions: The Implications for Public Reporting.

24. Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality.

25. Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and Outcomes.

26. Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment.

27. Ozone exposure and systemic biomarkers: Evaluation of evidence for adverse cardiovascular health impacts.

29. Assessing hospital performance for acute myocardial infarction: how should emergency department transfers be attributed.

30. Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease.

31. Weight-of-evidence evaluation of long-term ozone exposure and cardiovascular effects.

32. Weight-of-evidence evaluation of short-term ozone exposure and cardiovascular effects.

33. Comparison of intermediate-term outcomes of coronary artery bypass grafting versus drug-eluting stents for patients ≥75 years of age.

34. Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York.

35. Appropriateness of diagnostic catheterization for suspected coronary artery disease in New York State.

36. Risk stratification for long-term mortality after percutaneous coronary intervention.

37. Assessment of the new appropriate use criteria for diagnostic catheterization in the detection of coronary artery disease following noninvasive stress testing.

38. Underutilization of percutaneous coronary intervention for ST-elevation myocardial infarction in medicaid patients relative to private insurance patients.

39. Incomplete revascularization is associated with greater risk of long-term mortality after stenting in the era of first generation drug-eluting stents.

40. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.

41. Staged versus one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction.

42. 30-day readmission for patients undergoing percutaneous coronary interventions in New York state.

43. Impact of incomplete revascularization on long-term mortality after coronary stenting.

44. Comparison of outcomes for patients receiving drug-eluting versus bare metal stents for non-ST-segment elevation myocardial infarction.

45. Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for st-segment elevation myocardial infarction.

46. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease.

47. The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart.

48. Electrical alternans during rest and exercise as predictors of vulnerability to ventricular arrhythmias.

49. Predictors of fracture in the Accufix Atrial "J" lead.

50. Combined use of non-thoracotomy cardioverter defibrillators and endocardial pacemakers.

Catalog

Books, media, physical & digital resources